AtriCure (NASDAQ:ATRC) Price Target Raised to $64.00

AtriCure (NASDAQ:ATRC) had its target price upped by Needham & Company LLC from $45.00 to $64.00 in a research note released on Wednesday morning, Marketbeat.com reports. Needham & Company LLC currently has a buy rating on the medical device company’s stock.

Other research analysts also recently issued research reports about the stock. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Canaccord Genuity Group raised their target price on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. BTIG Research lifted their price target on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $52.00.

AtriCure Trading Down 1.8%

Shares of AtriCure stock opened at $51.52 on Wednesday. AtriCure has a 12-month low of $25.36 and a 12-month high of $53.50. The stock has a market cap of $2.62 billion, a P/E ratio of 245.35 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $40.10 and its 200-day moving average is $32.83.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts predict that AtriCure will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at AtriCure

In other news, insider Salvatore Privitera sold 7,763 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the completion of the sale, the insider owned 150,921 shares in the company, valued at approximately $7,923,352.50. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the sale, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. The trade was a 38.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 61,379 shares of company stock valued at $2,557,552. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently bought and sold shares of ATRC. AQR Capital Management LLC grew its position in shares of AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after purchasing an additional 8,956 shares during the period. Jane Street Group LLC grew its holdings in AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after buying an additional 87,553 shares in the last quarter. Finally, Strs Ohio acquired a new position in AtriCure in the 1st quarter valued at $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.